KAPA - Kairos Pharma Net Margin

Brandmark of Kairos Pharma Inc (KAPA)

Strong physician confidence in Kairos Pharma Ltd (KAPA) innovations sustains investor interest, as evidenced by the revenue margin indicator. The 0.00 mark indicates the current yield level. Business stability relies on the development of unique molecules in US centers, while the diversification of the clinical trial portfolio for prostate and lung cancer treatment minimizes potential failure risks.

Kairos Pharma Limited (KAPA) Company Sales Margin: for the period 09/17/2024 - 11/20/2026

Analytical breakdowns for kairospharma.com (KAPA)

- market value and analyst target forecast:
Summary company analytics:Kairos Pharma Inc - KAPA
Manufactured product of Kairos Pharma Ltd

The performance of Kairos Pharma Ltd (KAPA) is clearly reflected through the net sales margin spread. This indicator determines the portion of profit remaining from revenue after deducting all operating and tax expenses. The calculation allows for a precise measurement of the monetization efficiency of each product unit. For biotech companies, volatility in this metric often signals disruptions in raw material supply chains. Stable growth in the spread confirms the capital's resilience to geopolitical risks.

Competitor analysis

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|Net Margin Champions Oncology|Net Margin XBIT|Net Sales Margin CVM|Return on Sales by Net Profit OS Therapies Inc. OSTX|Net Margin Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Net Margin|ANL - Net Margin|Net Margin verupharma.com|TPST: Net Sales Margin|XLO - Company Sales Margin|Net Margin Renovaro|Net Sales Margin muraloncology.com|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)